Physician profile
Sameer Patel
NPI 1821258898
$4,497.41
in general payments reported to CMS, 2019-2025
8 companies · $2,768 in 2025
The $2,768 reported for 2025 was more than what 85% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $609 · 2021: $120 · 2022: $355 · 2023: $194 · 2024: $452 · 2025: $2,768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,600 · Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,600.00 |
| Food and Beverage | $813.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,403.87 | 2022-2025 | Signia |
| Angiodynamics, INC. | $609.13 | 2019 | |
| Ethicon US, LLC | $255.79 | 2021-2024 | Neuwave |
| Boston Scientific Corporation | $114.87 | 2024 | Tria Firm |
| Abbvie INC. | $70.35 | 2024-2025 | |
| Tela Bio, INC. | $24.21 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Alcresta Therapeutics, INC. | $19.19 | 2025 | Relizorb |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.